Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2021-11-19 00:00:00 ET · period of report 2021-11-19 · accession 0001883850-21-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-11-19 | 2021-11-19 | REGN | SCHLEIFER LEONARD S | Pres, CEO, Dir | M - OptEx | $221.08 | +520.3K | 651.6K | +396% | +$115.03M |
| DM | 2021-11-19 | 2021-11-19 | REGN | SCHLEIFER LEONARD S | Pres, CEO, Dir | F - Tax | $651.96 | -359.1K | 370.3K | -49% | -$234.14M |
| DM | 2021-11-19 | 2021-11-19 | REGN | SCHLEIFER LEONARD S | Pres, CEO, Dir | M - OptEx | $0.00 | -520.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-19 | M | A | 239,063 | $270.43 | 543,809 | D | — | — | |
| 2 | Common | Common Stock | 2021-11-19 | F | D | 185,646 | $651.96 | 465,922 | D | — | — | |
| 3 | Common | Common Stock | 2021-11-19 | M | A | 281,250 | $179.13 | 651,568 | D | — | — | |
| 4 | Common | Common Stock | 2021-11-19 | F | D | 173,491 | $651.96 | 370,318 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-11-19 | M | D | 239,063 | $0.00 | 0 | D | $270.43 · — to 2023-12-13 | 239,063 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |
| 6 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-11-19 | M | D | 281,250 | $0.00 | 0 | D | $179.13 · — to 2022-12-14 | 281,250 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |